Key result
Laroprovstat added to rosuvastatin cuts LDL-C by an additional ~51% vs. placebo.
Why the study?
Current PCSK9 inhibitors are injectable therapies, and no oral small-molecule PCSK9 inhibitor has yet been approved.
Does laroprovstat demonstrate safety, tolerability, and reduce LDL-C in healthy participants and treatment-naive patients with hypercholesterolemia?
RCT (n=108)
Single-blind
Randomized within the AstraZeneca randomization system (AZRand)
Does laroprovstat demonstrate safety, tolerability, and reduce LDL-C in healthy participants and treatment-naive patients with hypercholesterolemia?
Laroprovstat is the first oral small-molecule PCSK9 inhibitor to demonstrate robust LDL-C reduction and a favorable safety profile in Phase 1 clinical trials, supporting its further development.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Laroprovstat dosed with a statin would enable most patients to achieve their [LDL-C] goal and may lead to a reduction of cardiovascular risk and improved cardiovascular outcomes.”
Supports oral add-on to statin for deeper LDL-C reduction in hypercholesterolemia; extends PCSK9 inhibition to first-in-class small-molecule therapy.
BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved. METHODS: Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain. The effects of laroprovstat on LDL receptor expression and LDL-C levels were assessed in vitro and in mice expressing human PCSK9 . Safety, tolerability, and pharmacokinetic and pharmacodynamic properties of laroprovstat were assessed in healthy participants with LDL-C ≥70 and ≤190 mg/dL after single ascending doses. Laroprovstat was also assessed in participants with LDL-C ≥100 and ≤190 mg/dL at doses of 1 mg or 30 mg versus placebo administered once daily for 28 days after a rosuvastatin 20 mg run-in treatment period. RESULTS: Laroprovstat does not inhibit the PCSK9–LDL receptor interaction but stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and degradation of LDL receptor. Laroprovstat increased LDL receptor expression and reduced LDL-C levels in mice expressing human PCSK9 . Laroprovstat displayed dose-proportional pharmacokinetics and a half-life suitable for once-daily dosing (≈40 hours). There was no clinically meaningful change in exposure when dosed with a high-fat meal compared with the fasted state (AUC inf and C max geometric mean reduction of 1.15 [90% CI, 1.11–1.19] and 1.06 [90% CI, 1.00–1.13], respectively). After a rosuvastatin 20 mg 3-week run-in treatment period, laroprovstat 1 and 30 mg reduced LDL-C by 29% (95% CI, 38%–18%) and 51% (95% CI, 58%–44%) compared with baseline. Combined rosuvastatin and laroprovstat treatment resulted in a total approximate reduction in LDL-C of 70% and 80% for laroprovstat 1 and 30 mg, respectively. CONCLUSIONS: Laroprovstat was well tolerated with no safety findings of concern and may be dosed with or without food. In treatment-naive participants with hypercholesterolemia, combined rosuvastatin 20 mg and laroprovstat 30 mg treatment led to an 80% LDL-C reduction, supporting further development of laroprovstat as the first oral small-molecule PCSK9 inhibitor in patients with hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05384262.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Vega et al. (2026) conducted an RCT in Hypercholesterolemia (n=108). Laroprovstat (AZD0780) vs. Placebo was evaluated on Placebo-corrected change in LDL-C from baseline (MD -51%, 95% CI -58 to -44). In treatment-naive participants with hypercholesterolemia, laroprovstat combined with rosuvastatin reduced LDL-C by an additional 51% relative to placebo after 28 days.
Synapse has enriched 10 related papers. Consider them for comparative context: